BIOPOR Bioporto A/S

Grant of Warrants

Grant of Warrants

June 15, 2018

Announcement no. 11

In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has decided to issue 900,000 new warrants to BioPorto’s Chief Financial Officer, Ole Larsen, in connection with his employment in BioPorto A/S.

The issuance of new warrants will support the company's long-term goals and establish a performance-based remuneration reflecting the company's and shareholders' interests.

Each warrant grants the holder the right to subscribe for one share in the company. The exercise price is fixed at DKK 3.11 per share. Warrants will be exercisable from June 15, 2020 – June 14, 2023. Within the exercise period, warrants can be exercised within ordinary trading windows.

Conditions for cancellation of all warrants apply in case the Company does not achieve FDA approval of The NGAL Test™. The program also includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of e.g. takeover bid, resolution and business transfer.

Detailed terms of the warrants are to be found in the Articles of Association on under Investor Relations> Governance> Company Articles.

The total number of shares that the holder of warrants will be able to subscribe upon exercise of the warrants, are 900,000. The theoretical market value of the allocations of warrants amounts to DKK 575,475. The calculation is based on the Black-Scholes formula using an interest rate of -0.556% and the historical volatility of BioPorto A/S' shares of 24 months calculated to 37.6%.

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Gry Husby Larsen, General Counsel

Telephone , e-mail

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

Attachment

EN
15/06/2018

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S udnævner CFO

BioPorto A/S udnævner CFO 9. februar, 2026Meddelelse nr. 2 BioPorto A/S udnævner CFO BioPorto A/S (BioPorto) (CPH:BIOPOR) annoncerede i dag udnævnelsen af Klaus Juhl Wulff som ny Executive Vice President (EVP) og Chief Financial Officer (CFO) samt medlem af Executive Management-teamet senest pr. 1. maj 2026. Klaus Juhl Wulff er en højt kvalificeret leder med mere end 20 års erfaring inden for finans, drift, M&A og kapitalmarkeder. Han kommer til BioPorto fra AquaPorin A/S, hvor han var CFO fra 2022. Før dette har Klaus Juhl Wulff fungeret som CFO i forskellige virksomheder. Klaus Juhl W...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S Appoints Chief Financial Officer

BioPorto A/S Appoints Chief Financial Officer February 9, 2026Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, fin...

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering  5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering                                                                         KØBENHAVN, DANMARK, 5. februar, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH:BIOPOR), annoncerede i dag foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopd...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financ...

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update  February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update                                                                         COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update.                       ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Ændringer i selskabets Direktion

Ændringer i selskabets Direktion 11. december 2025 Meddelelse nr. 29 Ændringer i selskabets Direktion KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. december 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto") (CPH:BIOPOR) meddelte i dag, at Niels Høy Nielsen har opsagt sin stilling som CFO for BioPorto for at tiltræde en CFO-stilling i et andet selskab. "Jeg har værdsat det tætte samarbejde med Niels i de sidste par måneder, siden jeg tiltrådte min stilling i BioPorto. Niels har ydet vigtige bidrag til virksomheden og jeg ønsker ham alt det bedste i hans fremtidige stilling," sagde Carsten B...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch